ToxTalk
The official publication of the SOCIETY OF FORENSIC TOXICOLOGISTS, INC.

VOLUME 27 No. 2 JUNE 2003

IN THIS ISSUE . . .

- Elmer Gordon Open Forum
- Career Opportunities
- Professional Calendar
- Drugs in the News: Vioxx (Monforte)
- New Drugs: Aripiprazole (D Anderson)
- Case Notes Poly-Drug Intoxication with Methadone, Cocaine and Ethanol (G Behonick)
- Crossreactivity of Venlafaxine with a Phencyclidine Microplate Enzyme Immunoassay (Kemp)

In Memoriam: Dr. Joseph Balkon

INSERTS

- 2003 SOFT Directory (members only)
- 2003 SOFT meeting materials

October 20-24
Portland, OR

ToxTalk is mailed quarterly (bulk mail) to members of the Society of Forensic Toxicologists, Inc. It is each member’s responsibility to report changes of address to the SOFT mailing address (Mesa, AZ - above). Non-members may now receive ToxTalk for $15 per calendar year. Make your check payable to SOFT and mail it directly to the ToxTalk Editor.

DEADLINES: Feb. 1, May 1, Aug. 1, and Nov. 1.

NEXT DEADLINE: AUGUST 1, 2003
Portland and the Pacific Northwest! Images of mountains, the outdoors, the Pacific, magnificent sunsets, stately evergreen forests, rich Tillamook ice cream and cheeses, craft brewed beers... It's all true! And now it comes with all the forensic toxicology you can stand in the form of the 2003 SOFT annual meeting! We will be offering an exciting program on the most relevant topics in our field with all your old friends and colleagues as well as some special guests.

We are proud to invite you to join us October 20th - 24th, 2003, for workshops on methadone, forensic toxicology of metals, practical application of LCMS, emergency room toxicology, laboratory accreditation, weapons of mass destruction, new developments in antidepressants, regulated drug testing, and much more. The scientific program, in addition to your own valuable contributions, will also include our ERA award winners, a spotlight on drug impaired driving papers, and some special guests to give a more in-depth focus on some areas of interest to us all (details forthcoming).

Full details of the program are being updated regularly on the SOFT website at www.soft-tox.org. The abstracts deadline is June 1, and this year abstracts will be submitted online at the SOFT website. Also new this year is online registration! Visit the SOFT website now for all the latest news. See you in Portland!

**Hotel Accommodations:** The Doubletree Hotel Portland-Lloyd Center will be hosting our meeting. The 2003 convention rates will be:

- $128 for standard, one queen bed
- $138 for premium, two queen beds
- $138 for premium, one king bed

You can register online direct with the Portland Doubletree hotel at www.portlandlloydcenter.doubletree.com. Under special accounts enter the SOFT group code, which is SFT. Or you may call the hotel for reservations at (503) 281-6111. The deadline for hotel reservations to get the special SOFT group rate is September 28, 2003.

**Airport and Transportation:** You will be flying into the newly renovated Portland, PDX Airport, which is only about 10 miles from the hotel. Most of the major airlines have flights in and out of PDX on a regular basis. There is also light rail service (TriMet-MAX: www.tri-met.org) from the airport that makes a stop directly at the hotel and currently cost $1.55. The MAX Red Line operates between downtown Portland and the Portland International Airport (PDX), with no transfers required. This convenient light rail service, once at the hotel, is free anywhere within the major Portland downtown area. The hotel will also provide a limited free shuttle service to/from the airport. Rental car service is also available at the airport, and some rental car services are near the hotel.

**IMPORTANT DEADLINES:** Hotel registration deadline is Friday, September 28, 2003 to receive the special SOFT-2003 rates. The deadline for the SOFT-2003 meeting registration with no LATE FEES is Friday September 5, 2003. After September 5, 2003, there will be an additional $100 fee attached to all registrations. This will be a firm deadline. The deadline for all online meeting registrations, both ontime-online and online late registration, will be October 10, 2003. After October 10, 2003, only onsite registration will be available and the late fee will be applied.
SOFT 2003 Committee Members:

<table>
<thead>
<tr>
<th></th>
<th>Phone</th>
<th>FAX</th>
<th>E-mail</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meeting Hosts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kent Johnson</td>
<td>503-413-2069</td>
<td>503-413-4621</td>
<td><a href="mailto:kent.johnson1@attbi.com">kent.johnson1@attbi.com</a></td>
</tr>
<tr>
<td>Vickie Watts</td>
<td>480-236-4988</td>
<td>480-831-8091</td>
<td><a href="mailto:toxilady@aol.com">toxilady@aol.com</a></td>
</tr>
<tr>
<td>Scientific Program</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barry Logan, Ph.D.</td>
<td>206-262-6000</td>
<td>206-262-6145</td>
<td><a href="mailto:blogan@swp.wa.gov">blogan@swp.wa.gov</a></td>
</tr>
<tr>
<td>Ann Marie Gordon</td>
<td>206-262-6100</td>
<td>206-262-6145</td>
<td><a href="mailto:agordon@wsp.wa.gov">agordon@wsp.wa.gov</a></td>
</tr>
<tr>
<td>Vendor Liaison</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lisa O’Dell</td>
<td>303-477-5976</td>
<td>303-561-3803</td>
<td><a href="mailto:NomadLee9@aol.com">NomadLee9@aol.com</a></td>
</tr>
</tbody>
</table>

(Please note the correction to Kent Johnson’s e-mail - the other Kent Johnson will be grateful) ☀

ToxTalk NETWORK: Sharing problems and solutions

LAST CHANCE TO IDENTIFY YOUR FORENSIC TOXICOLOGY DEGREE OR CERTIFICATE SOURCE

Have no SOFT members been awarded a degree in forensic toxicology or been certified as a forensic toxicologist? Carl Selavka received no assistance in his quest to identify forensic toxicology undergraduate and graduate degree and certificate-granting programs in the U.S. Please contact Dr. Selavka at Cselavka@pol.state.ma.us with the following information:

- Name of the Academic Institution
- Best Person to Contact There
- Contact Person’s Phone Number & E-mail
- Type of Certificate or Degree(s) granted

2003 SOFT DIRECTORIES DISTRIBUTED

SOFT members will find their 2003 SOFT Directories enclosed with this issue of ToxTalk. If you have not yet paid your 2002 dues, your membership in SOFT has expired and your name has been removed from the directory. For reinstatement instructions contact the SOFT Administrative Office.

Please check your listing. If any information is not current or incorrect, contact the SOFT Administrative Office.

Reminder - If you do not pay your 2003 SOFT dues, your name will not appear in the next SOFT Directory. ☀

DON’T FORGET TO CHECK THE SOFT WEBSITE

www.soft-tox.org

Sections limited to SOFT members may be accessed by typing the username: drugs and password: #cocaine!

Unauthorized access or printing is protected by copyright laws. ☀

This is Patricia Mohn-Monforte’s 20th year working with SOFT. Originally, Pat helped coordinate the 1983 meeting in Detroit. She then was appointed Executive Coordinator for SOFT until 1995 and has performed the services of publisher of ToxTalk for about 16 years. Congratulations!
Venlafaxine is an antidepressant sold under the name Effexor®. Venlafaxine and its active metabolite O-desmethylvenlafaxine are both pharmacologically active, being potent inhibitors of serotonin and norepinephrine reuptake (1). Clinical studies have shown that a single oral dose of 50 mg produced an average peak plasma venlafaxine concentration of 0.07 mcg/mL (2). Chronic daily administration of 150 mg of venlafaxine produced an average steady state plasma concentration of 0.19 mcg/mL (3). Blood concentrations from deaths involving venlafaxine overdoses have ranged from 6.6 – 84 mcg/mL (4).

Our laboratory performs routine toxicology screening that includes microplate enzyme immunoassay (MPEIA) testing for drugs of abuse using assay kits from OraSure Technologies, Inc. (Bethlehem, PA) and the automated PersonalLab™ analyzer (Biochem Immunosystems, Allentown, PA). This report describes the discovery of the crossreactivity of both venlafaxine and O-desmethylvenlafaxine (O-DMV) with the phencyclidine (PCP) assay manufactured by OraSure. Our investigation into this interaction began with a postmortem case with a large blood concentration of venlafaxine (21.1 mcg/mL) and traces of atropine, nortriptyline and lidocaine. The MPEIA on blood was positive for PCP but was negative for PCP by both GC and GC/MS.

We explored the possibility of cross-reactivity with 9 of our postmortem cases that were positive for venlafaxine and negative for PCP. As can be seen in Table 1, optical density decreases with increasing concentrations of venlafaxine and/or O-DMV. For comparison, we included the OD for the PCP cutoff (10 ng/mL) and the negative calibrator (NCAL) from the batches in which the cases were run. We also included the mean OD from 9 cases that were negative for both venlafaxine and PCP. The only positive result was obtained with the highest concentration of venlafaxine. In addition, we spiked 2 blank blood samples with 1.0 and 20 mcg/mL venlafaxine, respectively. We also spiked a blank blood with 1.0 mcg/mL ODMV. The results are shown in Table 1.

The results of this limited experiment suggest that both venlafaxine and ODMV are cross-reactive with the OraSure PCP kit. The response in the case bloods is likely to be the result of the presence of both the parent and metabolite. This information may be useful for those laboratories using OraSure Technologies PCP assay kits.

Table 1: Blood venlafaxine concentrations and PCP/MPEIA Data

<table>
<thead>
<tr>
<th>concentration (mcg/mL)</th>
<th>OD</th>
<th>cutoff</th>
<th>NCAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.33</td>
<td>1.127</td>
<td>0.078</td>
<td>1.637</td>
</tr>
<tr>
<td>0.53</td>
<td>0.832</td>
<td>0.185</td>
<td>2.04</td>
</tr>
<tr>
<td>0.63</td>
<td>1.061</td>
<td>0.057</td>
<td>1.497</td>
</tr>
<tr>
<td>1</td>
<td>1.06</td>
<td>0.208</td>
<td>2.027</td>
</tr>
<tr>
<td>1.1</td>
<td>0.682</td>
<td>0.193</td>
<td>2.122</td>
</tr>
<tr>
<td>1.3</td>
<td>0.849</td>
<td>0.078</td>
<td>1.57</td>
</tr>
<tr>
<td>1.8</td>
<td>0.69</td>
<td>0.146</td>
<td>2.027</td>
</tr>
<tr>
<td>2</td>
<td>0.523</td>
<td>0.078</td>
<td>1.447</td>
</tr>
<tr>
<td>21.1</td>
<td>0.157</td>
<td>0.2</td>
<td>2.351</td>
</tr>
<tr>
<td>spiked venlafaxine</td>
<td>1.0</td>
<td>0.876</td>
<td>2.027</td>
</tr>
<tr>
<td>spiked venlafaxine</td>
<td>20.0</td>
<td>0.075</td>
<td>1.658</td>
</tr>
<tr>
<td>spiked ODMV</td>
<td>1.0</td>
<td>0.991</td>
<td>2.027</td>
</tr>
</tbody>
</table>

(See "references" on the next page)
References


NO on time + NO online = NO free stuff!!!!

Register for the 2003 SOFT meeting on the convenient SOFT website (http://www.soft-tox.org) no later than October 10th and you will receive an attractive, FREE polo-fleece jacket with an embroidered SOFT logo. You must register via the website before 10/10/23 to get the free jacket.

DRUGS IN THE NEWS

Vioxx

Submitted by Joseph R. Monforte, Ph.D., DABFT, Forensic Toxicology Consultant, Cave Creek, AZ

Arizonans who claim they have suffered heart attacks, strokes, or other ailments from taking the popular pain reliever Vioxx have joined plaintiffs in two other states who have sued or plan to sue the drug’s manufacturer. Forty-five plaintiffs in Maricopa Co. (AZ) and 20 in Pima Co. (AZ) filed lawsuits against Merck and Co. claiming that the company failed to warn them about possible side effects, including death. One plaintiff in each county claims that a relative died after taking Vioxx, approved by the FDA in May 1999. Other lawsuits have been filed in California and Utah.

AN INVITATION FROM TIAFT

TIAFT President Marilyn Huestis and Olaf Drummer, Chairperson of TIAFT’s 2003 Organizing Committee, invite their SOFT colleagues to participate in TIAFT’s 41st Annual Scientific Meeting, November 16-20, 2003, in Melbourne, Australia. Full details of the program can be obtained from the TIAFT site at http://www.tiaft.org/tiaft2003. Deadline for early bird registration and submission of abstracts is July 1, 2003. For further information regarding the meeting or associated workshops contact the chairperson: Prof. Olaf Drummer at olaf@vifp.monash.edu.au or Phone: +61 3 9684 4444 or fax: +61 3 9682 7353. Information on Melbourne may be accessed at http://www.visitmelbourne.com.au/.

SOFT looks forward to the next joint SOFT/TIAFT meeting in 2004 with SOFT meeting host Marc LeBeau in Washington, DC.
We previously reported the increased frequency of methadone-related deaths in our jurisdiction during a five year period 1997 to 2001. (1) We furthermore suggested an association with the recognized diversion and illicit use of oxycodone, principally in the form of OxyContin®. In CY2002 the Office of the Chief Medical Examiner, Western District of Virginia, certified 62 methadone-related deaths. This represents 32% of the total number of drug deaths in 2002 (n=195). The 62 cases represent a 26.5% increase from the previous year. The diversion and concomitant abuse of prescription drugs, particularly of the opiate and opioid classes, continues to significantly contribute to drug-related mortality. We describe a representative case report illustrating the pertinent postmortem toxicology and autopsy findings.

Case History: The decedent, a 38 year old white male, was described as having no significant past medical history. A family member indicated past heroin use by the decedent. Earlier during the day of his death, the decedent and a friend consumed large amounts of beer. The companion left the decedent during mid afternoon to go hunting. Upon returning at 7:15 PM, the witness found the decedent unresponsive on the floor near a sofa. Sheriff's deputies and EMS were summoned; however, resuscitative efforts and CPR were unsuccessful.

Autopsy Findings: External findings at autopsy revealed non-lethal bruises on the back and left side of the head consistent with falling injuries. Gross pathology was significant for coronary arteriosclerosis. Histological studies were remarkable for interstitial fibrosis with myocardial fiber hypertrophy in the heart, congestion and edema in the lungs with no polarizable crystals and periportal inflammation in the liver (portal triaditis).

Postmortem Toxicology:

<table>
<thead>
<tr>
<th>Blood</th>
<th>Vitreous Humor</th>
<th>Urine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethanol 0.21%</td>
<td>Ethanol 0.27%</td>
<td>Methadone present</td>
</tr>
<tr>
<td>Opiates ND*</td>
<td></td>
<td>Cocaine present, less than 0.02 mg/L</td>
</tr>
<tr>
<td>No acidic or neutral drugs detected</td>
<td></td>
<td>Cocaethylene 0.08 mg/L</td>
</tr>
<tr>
<td>Methadone 1.0 mg/L</td>
<td></td>
<td>Benzoylecgonine 1.4 mg/L</td>
</tr>
<tr>
<td>Cocaine none detected at 0.02 mg/L</td>
<td></td>
<td>No other alkali-extractable drugs detected</td>
</tr>
<tr>
<td>Cocaethylene none detected at 0.02 mg/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzoylecgonine 0.07 mg/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No other alkali-extractable drugs detected</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ND* Denotes not detected by FPIA screen

(Continued on the next page ... )
The cause of death in this case is combined narcotic drug, stimulant drug and alcohol poisoning due to usage of methadone, cocaine and ingestion of ethanol. A contributing cause is arterosclerotic heart disease. The interstitial myocardial fibrosis described in the heart may have been attributed to a narrowing of an artery or from prior cocaine use. The manner of death in this case is accident. Lethal toxicity is well described for the drugs methadone and cocaine (2-9). Of note in this case, there is no indication the decedent was actively participating in a drug recovery program utilizing methadone substitution therapy or had a valid prescription for the drug. The postmortem toxicology detected methadone and cocaine in combination and exemplifies an emerging trend in our jurisdiction. We initially observed this trend in the latter part of 2002 and we are continuing to investigate cases with this combination in the first part of 2003. The combination of an illicit street drug such as cocaine with a diverted prescription therapeutic agent such as methadone suggests a dangerous form of abuse often resulting in fatal outcomes.

References:


CALL FOR CASE NOTES

We need your contribution! This need not take much time.

Your case note should be about 1/2 page in length, no more than a full page is necessary. Material (arial font, size 10, Microsoft Word 6.0 preferred) may be submitted to:
Joseph R. Monforte, Ph.D., DABFT, ToxTalk Editor
E-mail: DrMonforte@aol.com

Other items of interest to SOFT members are also welcome.

NEXT DEADLINE: AUGUST 1, 2003
NEW DRUGS: Aripiprazole (Abilify®)

Submitted by D. Anderson, Los Angeles County Dept. of Coroner

Atypical Antipsychotic: Effective against both the positive and negative symptoms of schizophrenia
Manufactured by Bristol-Myers Squibb Co. in association with Otsuka Pharmaceutical CO. Ltd. (1999)
- Tablets: 10, 15, 20 & 30 mg
- FDA Approval Letter - Nov. 15, 2002
- Quinolinone Derivative
- Structure

\[ C_{23}H_{27}Cl_2N_3O_2 \]
MW=448

- pKa = ??
- Pharmacology
  - Dopamine D2 receptors
  - Presynaptic agonist
  - Postsynaptic antagonist
  - Affects the 5-HT Receptors
    - Antagonist at 5-HT2A
    - Partial agonist at 5-HT1A
- \( T_{1/2} \) 46.6 hrs
- Vd 4.9 L/kg
- Levels

Clinical Study

<table>
<thead>
<tr>
<th>Titrated Dose</th>
<th>Time (days)</th>
<th>Cmax (mg/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 mg/day</td>
<td>2</td>
<td>---</td>
</tr>
<tr>
<td>20 mg/day</td>
<td>2</td>
<td>---</td>
</tr>
<tr>
<td>30 mg/day</td>
<td>10</td>
<td>0.452 on day 14</td>
</tr>
</tbody>
</table>

- Adverse Effects: Sleepiness, headache, dullness, dizziness & insomnia.
- Minimal sedation & weight gain.
- Similar to other Atypical Antipsychotics such as
  - Clozapine
  - Quetiapine
  - Olanzapine
  - Risperidone
  - Ziprasidone

Oregon Visitor Information: www.traveloregon.com is the official website of the Oregon Tourism Commission. If you would like to order a free copy of The Official 2002 Oregon Travel Guide, 126 image-filled pages of helpful travel information about the State of Oregon, call 1.800.547.7842, or fill out the forms on this website.
IN MEMORIAM: JOSEPH BALKON, Ph.D., DABFT

We regret to inform you of the loss of our friend and colleague, Dr. Joseph Balkon, who died in his sleep on May 3rd from a massive heart attack.

If you look under "Presidents" in your SOFT Directory, you'll see "1982 Joseph Balkon, Ph.D." This is a small tribute to a man who played such a large role in the formation of the Society of Forensic Toxicologists. Joe had a strong leadership role in SOFT from its inception through the 1980's. I can recall Joe presenting a proposed logo to SOFT. His original design, rings representing Conway cells around a skull and crossbones, was adopted in 1980.

In addition to being a charter member, Dr. Balkon served SOFT as Treasurer (1979), Vice President (1981), President (1982), SOFT/JAT Special Issue Editor (1983), and member of various committees, including chair of the 1978 Certification Committee.

After graduating from SUNY Plattsburgh with his bachelor's degree in chemistry in 1970, Joe Balkon entered the field of Toxicology as a result of his first position as a toxicologist with the Toxicology Laboratory that was part of the Erie County (Buffalo) Laboratory system and the only tox lab in New York State west of the Hudson. He enrolled in St. John's University in 1973 to begin work on a master's Degree under the mentorship of Dr. Vincent DePaul Lynch, the originator of their under-graduate program in Toxicology- one of the first in the country! While a graduate student, Joe worked briefly with the Nassau County Medical Examiner Toxicology Lab under the supervision of Dr. Jesse Bidanset.

In 1975 he completed his MS in Toxicology, his research involving the development of a radioimmunoassay system for the detection of chlordiazepoxide in biological specimens. He also became Chief Toxicologist at the Long Island Jewish Hillside Medical Center. At LIJ he transformed a lab (with a two person staff) into a fully functioning clinical and forensic service employing state of the art techniques, including GCMS. Dr. Balkon completed his Ph.D. in 1978. His doctoral research involved the application of an immunoflorescence method to detect cellular dispositional characteristics of morphine in brain following therapeutic and toxic exposures and as a result of morphine addiction.

In 1981, Dr. Balkon joined the St. John’s University faculty full time where he was engaged in funded research (specializing in clinical and forensic toxicology, particularly in the area of fire toxicology), and mentored numerous students through their graduate work. He managed to teach, at some point, each of the courses in the under-graduate toxicology program as well as courses in pharmacology and graduate level courses in Toxicology.

Dr. Balkon's other professional commitments included Section Chair of the Toxicology Section of the American Academy of Forensic Sciences and Director of the American Board of Forensic Toxicology. In his professional practice, Dr. Balkon has served on distinguished expert panels evaluating medical examiners' systems, has appeared on radio and television ("20-20," "60 Minutes," "The Morton Downey Jr Show"), and has been involved as an expert in numerous legal cases on the local, state and federal level. In fact, one of the cases in which he testified resulted in a book in which he is featured ("Deadly Medicine). Joe's life was enriched by his wife, Nancy, and sons Bryan and Craig. Many SOFT members will well remember "Baby Bryan" at SOFT meetings and sharing the Balkons' joy when they announced the anticipated birth of Craig. Dr. Balkon's legacy includes a loving family, a wealth of friends and colleagues, and significant contributions to his profession.

Condolences may be sent to Nancy Balkon at 10 Spruce Court, Huntington, NY 11743.

The family suggests memorial contributions to the Joe Balkon Memorial fund, P.O. Box 80, Huntington, NY 11743.
ELMER GORDON OPEN FORUM
AN OPPORTUNITY FOR INFORMAL DIALOGUE

Congratulations to Mark Lewis who recently retired as Forensic Scientist of the New York State Police Forensic Investigation Center, Albany, New York, after 30 years of service. Mark began his career in toxicology in the 1960's under Tom Rejent. Watch out, members, Mark and Carol may show up at your door on their motorcycle!

The Monfortes want to thank all who have sent cards, notes, e-mails and some pretty cool gifts to Pat. You may have heard Pat Monforte lamenting that she'll be glad when she has something more interesting to talk about than her 3-yr-old accident. Be careful what you wish for! Many of you know that on March 15th (Beware the Ides of March!) Pat was hospitalized with spontaneous pulmonary emboli in the right lung. About a week later, she was released then admitted (by helicopter, no less!) the next day with an ultimate diagnosis of pulmonary emboli of the left lung. After 23 days in hospital, emergency pulmonary angiograms, CT scans, ultrasounds, a pharmaceutical cornucopia, two secondary infections, and enough blood draws to satisfy Dracula, Pat came home. Her recovery was initially very slow but is quite improved now. A big challenge is trying to maintain a therapeutic coumadin level - apparently, Pat isn't normal, but you already knew that.

Welcome to the wonderful world of grandparents. Don and Janet Kippenberger became the proud grandparents of Marshall Aron Kippenberger in March. 

6th/7th ANNUAL S.O.F.T.
TOX'N PURGE MICHIGAN TO OREGON FUN RUN/WALK

2003 SOFT Meeting
Doubletree Hotel Portland
Portland, Oregon

Tuesday
October 21st
6:30 A.M.

Registration includes:
1st Place Prizes
(men and women)
Random drawings
T-shirt

Entry fee: $7

SEE THE MEETING PACKET INCLUDED WITH THIS ISSUE OF TOXTALK FOR DETAILS AND REGISTRATION FORM
**SOFT 2003 ANNUAL MEETING**

Doubletree -Lloyd Center, Portland, Oregon

October 20-24, 2003

**WEBSITE REGISTRATION WORKSHEET**

You must register online to receive the FREE polo-fleece jacket with embroidered SOFT logo and a ticket to the President's reception at the OMSI museum.

SOFT Registration on the SOFT website is through PayPal, a secure site, which accepts the most major credit cards or payment through routing of checks drawn on a US bank or International Bank. It's easy! DEADLINE: OCTOBER 10, 2003.

- Type the information requested (your name, degree, the name to appear on your badge, title, agency, address, e-mail, telephone, fax, accompanying person/s).
- Make your meeting selections as noted below
- Complete the credit card payment information

<table>
<thead>
<tr>
<th></th>
<th>Member</th>
<th>Non-Member</th>
<th>Qty.</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FULL MEETING REGISTRATION</strong> (Late Fee Applies after 9/05/03)</td>
<td>$185.00</td>
<td>$275.00</td>
<td></td>
<td>Enter jacket size online</td>
</tr>
<tr>
<td>Includes: Admission to scientific sessions, Abstract Book, SOFT jacket, Coffee Breaks, Continental Breakfasts, Welcoming Reception, Luncheons, Tuesday Happy Hour, Elmer Gordon Forum, and President's Reception</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **ACCOMPANYING PERSON REGISTRATION** (Available only with full meeting registration) | $150.00 | $225.00 | | |
| Includes: All the above except Abstract Book and Jacket |

| **FULL-TIME STUDENT** (Proof of full-time status required) | $95.00 | $95.00 | | |

| **LATE-FEE** (Applies after September 5 to EACH of above registrations) | $100.00 | $100.00 | | |
| After October 10, 2003 – only On-Site Registration is available |

| **PRESIDENT’S RECEPTION – ADDITIONAL TICKETS** (Additional tickets for non-registrants only available prior to October 10) | $75.00 | $95.00 | | |

| **ON-SITE REGISTRATION** (President’s Reception and polo-fleece jacket NOT included) | $285.00 | $375.00 | | |
| Workshop # 1: Chemical, Biological and Nuclear Threat: Challenges for the Toxicologist. | $100.00 | $150.00 | | |
| Workshop # 2: Forensic Toxicology of Metals | $50.00 | $75.00 | | |
| Workshop # 3: Principles of Sample Preparation | $50.00 | $75.00 | | |
| Workshop # 4: Practical Applications for LCMS in Routine Toxicology | $50.00 | $75.00 | | |
| Workshop # 5: Forensic Toxicology of Methadone | $50.00 | $75.00 | | |
| Workshop # 6: Feeling Blue? Antidepressant Workshop! | $100.00 | $150.00 | | |
| Workshop # 7: Preparation and Planning for Laboratory Accreditation by the American Board of Forensic Toxicology (ABFT). | $50.00 | $75.00 | | |
| Workshop # 8: Developments in Federally Regulated Drug Testing | $50.00 | $75.00 | | |
| Workshop # 9: Toxicology in the Emergency Room | $50.00 | $75.00 | | |
| Workshop # 10: Developments in Pharmacology of Antiepileptic Drugs | $50.00 | $75.00 | | |
| ABFT Breakfast (Diplomates and Specialists) | $25.00 | $25.00 | | |

**ID BADGE WILL BE REQUIRED FOR ALL FUNCTIONS. TICKET REQUIRED FOR PRESIDENT’S RECEPTION.**

See insert for mail registration directions.

ToxTalk Volume 27 No. 2

JUNE 2003
CAREER OPPORTUNITIES

Positions available are listed for the consideration of SOFT members. There is no fee for this service. The information will be repeated in the next issue only if the person who submitted it confirms the information. If you have a job position available, e-mail ToxTalk Editor Monforte at DrMonforte@aol.com.

SENIOR BIOANALYST/MASS SPECTROMETRIST: Ph.D. or education+experience and at least 3 yrs GC or LC-MS/MS experience required. Investigate and apply new existing technologies for the screening and confirmation of abused substances in oral fluids; develop testing methods for drugs abused by healthcare professionals from various bio matrices; and develop, validate and apply quantitative/semi-quantitative LC-MS/MS and GC-MS/MS methods for these drugs and metabolites. Contact Michael Feldman, Northwest Drug Testing, Salt Lake City: mfeldman@nwtinc.com

PROFESSIONAL CALENDAR

SOFT MEETINGS:

October 20-24
Portland, OR
Hosts: Kent Johnson
Vickie Watts

2004 Washington, D.C. - Marc LeBeau
2005 Nashville, TN - Louis Kuyendall
2006 Austin, TX - Rod McCutcheon
2007 Chapel Hill, NC - Ruth Winecker
2008 Phoenix, AZ - Vickie Watts
2009 Oklahoma City, OK - Phil Kemp

California Association of Toxicologists - Quarterly Meeting: August 1-2, 2003, Santa Rosa, CA. Theme: Alcohol-related topics; speakers will include Alan Wayne Jones and other recognized experts in the field of alcohol research. Contact Gregory A. Priebe, California Department of Justice, 7505 Sonoma Highway, Santa Rosa, CA 95409 Phone: 707-576-2415 Fax: 707-576-2141 Greg.Priebe@doj.ca.gov

2nd Summer Conference on Current Topics in Forensic Toxicology: August 28-30, 2003, UCLA Extension. Contact Sheila King at sking@unex.ucla.edu for more information.

8th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology: September 7-22, 2003, Basel, Switzerland. Contact www.ictdmet2003.ch

29th Annual Meeting of the Northeastern Association of Forensic Scientists: November 5-8, 2003, Pittsfield, MA. Contact Jennifer Limoges at jlimoges@troopers.state.ny.us or tel: 518-457-0054


All members and others are encouraged to contribute to ToxTalk. Please submit your contribution to:
Joseph R. Monforte, Ph.D., DABFT, ToxTalk Editor, by e-mail at DrMonforte@aol.com